Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02718300 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT02718300 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 74 participants.
The verdict
NCT02718300, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
Interventions
- DRUG Ruxolitinib
- DRUG Parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2022-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02718300
The ClinicalTrials.gov registry entry for NCT02718300 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT02718300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02718300 about?
NCT02718300 is a clinical study titled "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis". The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
What is the current status of trial NCT02718300?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2017-02-08. Estimated completion is 2022-04-29.
What interventions are being tested in trial NCT02718300?
The interventions under investigation include: Ruxolitinib (DRUG), Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT02718300?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.